FiercePharma

GSK ViiV's Dovato squares off against Evofem's Phexxi in final #FierceMadness DTC ad matchup

The final showdown is set in the FierceMadness DTC ad contest. Dovato from GlaxoSmithKline’s ViiV Healthcare will go up against Phexxi from Evofem Biosciences for the championship title. Phexxi, the ...
Business Wire

ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented 48-week data from the SALSA ...
Morningstar

ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain

In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...
Business Wire

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented three-year results from the ...
Nasdaq

ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

Dovato, a complete, once-daily, single-tablet, two-drug regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg, allows adults living with HIV the option to manage their virus without a third ...